Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra®

Abstract

PT-141, a cyclic heptapeptide melanocortin analog, was evaluated following subcutaneous administration to healthy male subjects and to patients with erectile dysfunction (ED) who report an inadequate response to Viagra®. An inadequate response was defined for this study by patient report indicating that achievement of an erection suitable for vaginal penetration occurred ≤50% of the time while taking 100 mg Viagra®. Erectile responses were assessed by RigiScan™ in healthy subjects in the absence of visual sexual stimulation (VSS) and in ED patients in the presence of VSS. Doses ranging from 0.3 to 10 mg were administered to healthy male subjects, resulting in a statistically significant erectile response at doses greater than 1.0 mg. ED patients were treated with placebo, 4 or 6 mg PT-141 in a crossover design in the presence of VSS. The erectile response induced by PT-141 was statistically significant at both doses. PT-141 was safe and well tolerated in both studies. The erectogenic potential of PT-141, its tolerability profile and its ability to cause significant erections in patients who do not have an adequate response to a PDE5 inhibitor suggest that PT-141 may provide an alternative treatment for ED with a potentially broad patient base.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

References

  1. Lue TF . Erectile dysfunction. N Engl J Med 2000; 342: 1802–1813.

    CAS  Article  Google Scholar 

  2. Goldstein I et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397–1404.

    CAS  Article  Google Scholar 

  3. Porst H et al. The efficacy and tolerability of Vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001; 13: 192–199.

    CAS  Article  Google Scholar 

  4. Padma-Nathan H et al. On-demand IC351 (Cialis™) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 2001; 13: 2–9.

    CAS  Article  Google Scholar 

  5. Padma-Nathan H, Steers WD, Wicker PA . Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Int J Clin Pract 1998; 52: 375–379.

    CAS  PubMed  Google Scholar 

  6. Rendell MS, Rajfer J, Wicker PA, Smith MD . Sildenafil for treatment of erectile dysfunction in men with diabetes. JAMA 1999; 281: 421–426.

    CAS  Article  Google Scholar 

  7. McCullough A, Woo K, Telegrafi S, Lepor H . Is sildenafil failure in men after radical retropubic prostatectomy (RRP) due to arterial disease? Penile duplex Doppler findings in 174 men after RRP. Int J Impot Res 2002; 14: 462–465.

    CAS  Article  Google Scholar 

  8. Hatzichristou DG . Sildenafil citrate: lessons learned from 3 years of clinical experience. Int J Impot Res 2002; 14(Suppl 1): S43–S52.

    Article  Google Scholar 

  9. Souverein PC et al. Incidence and determinants of sildenafil (dis) continuation: the Dutch cohort of sildenafil users. Int J Impot Res 2002; 14: 259–265.

    CAS  Article  Google Scholar 

  10. Andersson K-E, Hedlund P . New directions for erectile dysfunction therapies. Int J Impot Res 2002; 14(Suppl 1): S82–S92.

    Article  Google Scholar 

  11. Wessells H et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology 2000; 56: 641–646.

    CAS  Article  Google Scholar 

  12. Molinoff PB et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann NY Acad Sci 2003; 994: 96–102.

    CAS  Article  Google Scholar 

  13. Gantz I et al. Molecular cloning of a novel melanocortin receptor. J Biol Chem 1993; 268: 8246–8250.

    CAS  PubMed  Google Scholar 

  14. Gantz I et al. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J Biol Chem 1993; 268: 15174–15179.

    CAS  PubMed  Google Scholar 

  15. Diamond LE et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 2004; 16: 51–59.

    CAS  Article  Google Scholar 

  16. Rosen RC et al. The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–830.

    CAS  Article  Google Scholar 

  17. Capelleri JC et al. Diagnostic evaluation of the erectile function domain of the international index of erectile function. Urology 1999; 54: 346–351.

    Article  Google Scholar 

  18. Wikberg JE et al. New aspects on the melanocortins and their receptors. Pharmacol Res 2000; 42: 393–420.

    CAS  Article  Google Scholar 

  19. Argiolas A, Melis MR, Murgia S, Schioth HB . ACTH-and alpha-MSH-induced grooming, stretching, yawning and penile erection in male rats: site of action in the brain and role of melanocortin receptors. Brain Res Bull 2000; 51: 425–431.

    CAS  Article  Google Scholar 

  20. Argiolas A, Melis MR, Gessa GL . Yawning and penile erection: central dopamine–oxytocin–adrenocorticotropin connection. Ann NY Acad Sci 1988; 525: 330–337.

    CAS  Article  Google Scholar 

  21. Van der Ploeg LHT, Martin WJ, Howard AD, Nargund RP . A role for the melanocortin 4 receptor in sexual function. Proc Natl Acad Sci USA 2002; 99: 11381–11386.

    CAS  Article  Google Scholar 

  22. McKinlay JB . The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000 Oct 12; (Suppl 4): S6–S11.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R C Rosen.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Rosen, R., Diamond, L., Earle, D. et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra®. Int J Impot Res 16, 135–142 (2004). https://doi.org/10.1038/sj.ijir.3901200

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901200

Keywords

  • pharmacologic studies in sexual function
  • oral vasoactive agents

Further reading

Search

Quick links